Description: Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Home Page: www.almirall.com
Ronda Del General Miter, 151
Barcelona,
08022
Spain
Phone:
34 93 291 30 00
Officers
| Name | Title |
|---|---|
| Mr. Carlos Gallardo Piqué | Interim CEO & Pres of the Board |
| Mr. Michael McClellan | Exec. VP of Fin., CFO & Member of Management Board |
| Mr. Joan Figueras Carreras | Vice Sec., Member of Mgmt. Board, Non-Voting Director & Exec. Director of Corp. Governance |
| Mr. Eloi Crespo Cervera | Sr. VP of Industrial Operations & Member of Management Board |
| Mr. Jordi Sabé Richer | Sr. VP of Corp. Devel. & Member of Management Board |
| Mr. Esteve Conesa Panicot | Sr. VP of HR & Member of Management Board |
| Dr. Volker Koscielny | Chief Medical Officer & Member of Management Board |
| Mr. Pablo Alvarez | Member of Management Board, Pres of Almirall US & GM of Almirall US |
| Dr. Karl Ziegelbauer | Exec. VP of R&D, CSO and Member of Management Board |
| Mr. Paolo Cionini | Chief Commercial Officer Europe & International and Member of Management Board |
Exchange: MC
Country: ES
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 29.1545 |
|---|---|
| Trailing PE: | 56.75 |
| Price-to-Book MRQ: | 1.2206 |
| Price-to-Sales TTM: | 1.8904 |
| IPO Date: | 2007-06-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 1786 |